Navigation Links
Pharma IQ's Solubility Report
Date:4/27/2012

LONDON, April 27, 2012 /PRNewswire/ --

Pharma IQ has just published the results of an industry-wide Solubility Report, conducted recently among 3,000 pharmaceutical solubility specialists.

The results showed that improving API solubility is the greatest challenge for nearly 60% of respondents, followed by exploring novel drug delivery routes (specified by 26% of respondents). The rest of the survey participants indicated improving API stability and formulation of biopharmaceuticals as the major issues.

In terms of improving compound solubility, the most popular compound modification strategies used by respondents were developing an amorphous form and adding an excipient. The least popular ones were changing the crystal structure and addition of a salt.

The report was created as a part of the pre-conference research for Improving Solubility Forum, taking place 26-28 June, 2012 in Munich.

The results helped to shape the agenda and final speaker line-up, which features David Elder, Externalisation Director from GlaxoSmithKline who will present his thoughts on model guided formulation development and Lennart Lindfords, Pharmaceutical and Analytical R&D from AstraZeneca, who will be leading a session on Computer Calculations of Poorly Soluble Drug Transport Across the Gastrointestinal Cell Wall.

Other important topics expressed by survey respondents and that will be discussed at the event include:

  • The Impact of Solubility During Pharmaceutical Research and Development (Christoph Saal, Senior Manager Molecule Characterisation, Merck)
  • The impact of surfactants on dissolution, in-vitro permeability and bioavailability of poorly soluble drugs (Menno Vliestra, Global Supply Chain, Finance and HR, Roche)
  • The use the knowledge and exp
    '/>"/>

SOURCE Pharma IQ
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... provides most accurate view inside human body ... meeting of the American Society for Reproductive Medicine got ... the presentation of endoscopic gynecologic surgery performed for the ... F. Palter, MD, an obstetrician, gynecologist, reproductive endocrinologist and ...
... The Roy and Patricia Disney Family Cancer Center will be the ... to own all the latest oncology products from Elekta ... CMS software. , Rex Hoffman, M.D. is Medical Director ... Roy and Patricia Disney Family Cancer Center will be located. He ...
Cached Medicine Technology:Long Island Doctor Shows First '4K' Ultra-High Definition Surgery 2Long Island Doctor Shows First '4K' Ultra-High Definition Surgery 3Elekta Provides Complete Planning, Treatment and Workflow Solution for Roy and Patricia Disney Family Cancer Center 2Elekta Provides Complete Planning, Treatment and Workflow Solution for Roy and Patricia Disney Family Cancer Center 3
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
(Date:4/17/2014)... days to find a colored ribbon representing a disease. A ... what color ribbon does one think of with lung cancer?, ... many suffering from the disease, black may be the only ... of lung cancer patients, primarily smokers between the ages of ... the stigma often felt by these patients, the emotional toll ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... expert says, , WEDNESDAY, July 22 (HealthDay News) -- When ... kind of snack that matters, but who eats it. , ... women, the healthy-weight women wanted less of the treat over ... non-obese women respond to high-energy, high-density snacks in different ways," ...
... , , IRVINE, Calif., July ... Pulse CO-Oximetry and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced it ... 4, 2009 after the market closes on Tuesday, August 4, 2009. , ... results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will ...
... , , , ... July 22 Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. ... cooperative group-sponsored randomized Phase 2 trial in advanced metastatic breast ... evaluated Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic, ...
... , , BATON ROUGE, ... manage cleanup efforts in hurricane-ravaged areas. Assisting in the diagnosis and ... which one is practically required to live at the gym and work ... careers are both varied and interesting. . .many of them coming with ...
... ... HSA Bank, two innovators in health savings accounts, have announced a new marketing ... easy access to HSA Bank through the My HSA Rewards website to learn ... HSA Bank customers will be given the opportunity to enroll in My HSA ...
... The Centers ... much as 4.5 percent by the year 2010. The additional costs could be passed along ... ... likely increase costs to seniors for their Medicare Advantage health insurance plans, in April the ...
Cached Medicine News:Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 2Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 3Health News:Masimo to Report Second Quarter 2009 Financial Results on August 4, 2009 2Health News:Masimo to Report Second Quarter 2009 Financial Results on August 4, 2009 3Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 2Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 3Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 4Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 5Health News:Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer 6Health News:MedVance Institute To Offer New High-Demand Courses 2Health News:MedVance Institute To Offer New High-Demand Courses 3Health News:HSA Bank and My HSA Rewards Offer a New Way for HSA Bank Customers to Help Pay for Their Health Care 2Health News:HSA Bank and My HSA Rewards Offer a New Way for HSA Bank Customers to Help Pay for Their Health Care 3Health News:Medicare Agency Announces Decreased Payments to Medicare Advantage Insurers in 2010, Says MedicareSupplementPlans.com 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: